#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

A lit­tle more than a year af­ter Yescar­ta was ap­proved as the first CAR-T for third-line ther­a­py in large B-cell lym­phoma, re­searchers are still try­ing to de­ter­mine what the me­di­an over­all sur­vival rate for pa­tients is. It hasn’t been reached.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER